TriSalus Life Sciences, Inc. (TLSI)

TriSalus Life Sciences' stock (TLSI) has experienced several notable events in the past six months. The share price increased by 24.25% between November 18, 2024, and November 14, 2025, and over the last year, the stock price increased by 49.77%. In Q1 2025, the company reported $9.2 million in net sales, a 42% increase over Q1 2024, and an 11% sequential gain over Q4 2024. In Q2 2025, TriSalus delivered $11.2 million in net sales, marking a 52% year-over-year increase and 22% sequential growth over Q1 2025. In Q3 2025, Revenue reached $11.6 million, a 57% increase year-over-year and a 3% sequential gain over Q2 2025. Full-year 2024 revenue was $29.4 million, a 59% increase over 2023. The company launched the TriNav FLX infusion system and the TriNav XP Infusion System, expanding its Pressure-Enabled Drug Delivery portfolio. The Centers for Medicare and Medicaid Services (CMS) issued a new HCPCS code (C8004) for TriNav mapping procedures, which is expected to expand the reimbursable use of TriNav.

TriSalus Life Sciences has indicated that its sequential revenue growth reflects expected seasonal trends, suggesting that the demand for TriSalus's products and services may fluctuate throughout the year according to predictable patterns.

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company dedicated to improving outcomes for patients with difficult-to-treat liver and pancreatic cancers. The company operates within the Healthcare sector, specifically in the Medical Devices and Biotechnology & Medical Research industries, and its core business revolves around its proprietary Pressure-Enabled Drug Delivery (PEDD) approach. Its major products include the TriNav Infusion System, a Pancreatic Retrograde Venous Infusion device, and Nelitolimod (SD-101).

TriSalus Life Sciences, Inc. is headquartered in Westminster, Colorado, United States, and the sales of its TriNav device are primarily driven within the U.S. market.

TriSalus Life Sciences' brand reputation in the past year appears to be primarily shaped by its advancements in product development and financial performance. The company has consistently reported strong revenue growth and expanded its product portfolio with the launch of new TriNav systems. While the company has shown significant revenue growth, it has also reported declining gross margins in some quarters and increased R&D and operating losses. The decision to shift nelitolimod to a partnership-focused strategy aims to reduce development expenses while preserving the program's long-term value.

TriSalus Life Sciences, Inc. has a diverse ownership structure. Institutions hold 17.23% of the stock, while 2.58% is owned by institutional investors. TriSalus Life Sciences insiders own 41.95% of the company. Retail investors hold 40.82% of the stock.